TC
NKTR icon

TFS Capital’s Nektar Therapeutics NKTR Stock Holding History

TFS Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,630
Closed -$300K – 788
2016
Q4 		$300K Buy
+1,630
New +$331K 0.08% 408
2016
Q2 		– Sell
-1,182
Closed -$244K – 1114
2016
Q1 		$244K Sell
1,182
-1,291
-52% -$248K 0.04% 712
2015
Q4 		$625K Buy
+2,473
New +$509K 0.07% 377
2015
Q3 		– Sell
-17,731
Closed -$3.33M – 997
2015
Q2 		$3.33M Buy
+17,731
New +$3.05M 0.33% 65
2014
Q4 		– Sell
-2,455
Closed -$444K – 1098
2014
Q3 		$444K Sell
2,455
-1,100
-31% -$211K 0.04% 634
2014
Q2 		$684K Sell
3,555
-21,589
-86% -$3.82M 0.05% 533
2014
Q1 		$4.57M Buy
+25,144
New +$4.98M 0.3% 49
2013
Q4 		– Sell
-19,137
Closed -$3M – 1575
2013
Q3 		$3M Buy
19,137
+5,675
+42% +$1.05M 0.14% 203
2013
Q2 		$2.33M Buy
+13,462
New +$2.06M 0.1% 307

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TFS Capital's NKTR Position: Q1 2017 in Review

TFS Capital sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 1,630 shares — an estimated $300K sold.

TFS Capital first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $4.57M in Q1 2014. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • TFS Capital reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 1,630 Nektar Therapeutics shares in Q1 2017, an estimated $300K.
  • TFS Capital first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
  • TFS Capital's Nektar Therapeutics position peaked at $4.57M in Q1 2014.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.